^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCR4 positive

    i
    Other names: CCR4, C-C Motif Chemokine Receptor 4, CC-CKR-4, CMKBR4, K5-5, Chemokine (C-C Motif) Receptor 4, C-C Chemokine Receptor Type 4, C-C CKR-4, ChemR13, CD194, CCR-4, CKR4, Chemokine (C-C) Receptor 4, CD194 Antigen, HGCN:14099
    Entrez ID:
    1233
    Related biomarkers:
    Expression
    3ms
    Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma. (PubMed, Br J Dermatol)
    No abstract available
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    CCR4 positive
    |
    Poteligeo (mogamulizumab-kpkc)
    4ms
    C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation. (PubMed, Eur J Cancer)
    The recruitment of CCR4 + Tregs to the postirradiated TME increases the metastatic potential of tumor cells through increased interactions with M2-type TAMs. A significant reduction in post-RT lung metastases in ectopic mouse models was achieved by disrupting the recruitment of both CCR4 + Tregs and CCR2 + myeloid cells, which are TAM precursors.
    Journal • Metastases
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • CCL2 (Chemokine (C-C motif) ligand 2) • CCR2 (C-C Motif Chemokine Receptor 2)
    |
    CCR4 positive
    5ms
    Impact of Mogamulizumab-Containing Chemotherapy on HBV Reactivation in Patients with T-Cell Lymphoma: A Multicenter Retrospective Observational Study (PROACTIVE-MOGA) (ASH 2023)
    Our current study showed that the risk of HBVR was 4. 3% (1 of 23) among HBsAg-positive patients with antiviral prophylaxis and 4. 6% (11 of 238) among resolved HBV-infected patients without antiviral prophylaxis following Moga-containing chemotherapy.
    Observational data • Retrospective data
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    CCR4 positive
    |
    Poteligeo (mogamulizumab-kpkc)
    5ms
    North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351 (ASH 2023)
    This is because, although an anti-CCR4 mAb, mogamulizumab, has been approved in Japan to treat ATLL, this therapy failed in a Phase 2 trial among patients outside of Japan. CCL22 but not CCL17 induced strong chemotaxis behavior in NA-ATLL cell lines, which was potently inhibited by a small molecule CCR4 antagonist, CCR4-351. Since extramedullary presentation is frequently seen in NA-ATLL and central nervous system involvement is an adverse prognostic feature, inhibiting chemotaxis with a CCR4 antagonist such as FLX475 may be an effective therapeutic approach.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CD7 (CD7 Molecule) • CCL22 (C-C Motif Chemokine Ligand 22)
    |
    CCR4 positive
    |
    Poteligeo (mogamulizumab-kpkc) • tivumecirnon (FLX475)
    6ms
    One case of CCR4 -positive adult T -cell leukemia/lymphoma that was found to be found in chest pain and mediastinal expansion (JLCS 2023)
    No abstract available
    Clinical
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    CCR4 positive
    6ms
    Mogamulizumab for Refractory CD3-CD4+ Lymphocytic-Variant Hypereosinophilic Syndrome (ASH 2023)
    Hematological responses to mogamulizumab in four refractory lymphocytic HES patients. OCS: oral corticosteroids; pINF-α: pegylated interferon alpha; MEPO: mepolizumab; MOGA: mogamulizumab.
    IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • IL5 (Interleukin 5)
    |
    CCR4 positive
    |
    Poteligeo (mogamulizumab-kpkc)
    1year
    A PHASE 2 TRIAL OF CHOP WITH ANTI-CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4-POSITIVE ADULT T-CELL LEUKEMIA/LYMPHOMA (ICML 2023)
    We assessed the efficacy of an anti-CCR4 antibody, mogamulizumab (Moga)combined with biweekly cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PSL) (Moga-CHOP-14) for untreated elderly patients with aggressive ATL. This study demonstrated that Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive CCR4-positive ATL who were ineligible for allo-HSCT. Moga-CHOP-14 is now considered for the preferred first-line treatment in those patients. Clinical trial ID:jRCTs041180130.
    Clinical • P2 data
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    CCR4 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Poteligeo (mogamulizumab-kpkc)
    1year
    A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma. (ASCO 2023)
    We assessed the efficacy of an anti-CCR4 antibody, mogamulizumab (Moga) combined with biweekly cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PSL) (Moga-CHOP-14) for untreated elderly patients with aggressive ATL. This study demonstrated that Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive CCR4-positive ATL who were ineligible for allo-HSCT. Moga-CHOP-14 is now considered for the preferred first-line treatment in those patients. Clinical trial information: jRCTs041180130.
    Clinical • P2 data
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    CCR4 positive
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • Poteligeo (mogamulizumab-kpkc)